4.82
+0.15
(3.21%)
Jun 18 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 4.61 - 4.82 |
| 52 week | 4.19 - 6.95 |
| Open | 4.68 |
| Vol / Avg. | 0.00/1.34M |
| Mkt cap | 885.92M |
| P/E | - |
| Div/yield | - |
| EPS | -0.97 |
| Shares | 183.80M |
| Beta | 1.92 |
| Inst. own | 85% |
Events
Jul 29, 2013
Q2 2013 Exelixis, Inc. Earnings Release
Jun 12, 2013
Exelixis, Inc. at William Blair Growth Stock Conference -
Jun 11, 2013
Exelixis, Inc. at Goldman Sachs Healthcare Conference -
Jun 2, 2013
Exelixis, Inc. at American Society of Clinical Oncology (ASCO) 2013 Annual Meeting -
May 21, 2013
Exelixis, Inc. at UBS Global Healthcare Conference -
May 14, 2013
Exelixis, Inc. at Bank of America Merrill Lynch Health Care Conference -
May 7, 2013
Q1 2013 Exelixis, Inc. Earnings Conference Call -
Apr 29, 2013
Q1 2013 Exelixis, Inc. Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -462.60% | -311.16% |
| Operating margin | -351.74% | -258.03% |
| EBITD margin | - | -226.66% |
| Return on average assets | -25.99% | -26.50% |
| Return on average equity | -65.09% | -76.29% |
| Employees | 174 | - |
| Carbon Disclosure Rating | - | - |
Address
210 East Grand Ave.
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-8377000 (Phone)
+1-650-8378300 (Fax)
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-8377000 (Phone)
+1-650-8378300 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. The clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer (CRPC) and medullary thyroid cancer but also includes the evaluation of other tumor types. Cabozantinib inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth, vascularization and/or metastasis.
Officers and directors
| Stelios B. Papadopoulos Ph.D. | Independent Chairman of the Board | |
| Michael M. Morrissey Ph.D. | President, Chief Executive Officer, Director | |
| Frank L. Karbe | Chief Financial Officer, Executive Vice President | |
| Peter Lamb Ph.D. | Executive Vice President - Discovery Research, Chief Scientific Officer | |
| Pamela A. Simonton J.D. | Executive Vice President, General Counsel | |
| J. Scott Garland | Executive Vice President, Chief Commercial Officer | |
| Gisela M. Schwab M.D. | Executive Vice President, Chief Medical Officer | |
| Charles M. Cohen Ph.D. | Independent Director | |
| Carl B. Feldbaum Esq. | Independent Director | |
| Alan M. Garber M.D., Ph.D. | Independent Director |